8-K: INmune Bio Secures $65M ATM Equity Offering

INmune Bio Inc. has entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell up to $65 million of its common stock through an at-the-market offering.

Summary

• INmune Bio Inc. (the Company) entered into a Sales Agreement with A.G.P./Alliance Global Partners (A.G.P.) on December 19, 2025.
• The agreement allows the Company to offer and sell, from time to time, up to $65,000,000 of its common stock through A.G.P. as a sales agent.
• The Company is not obligated to sell any shares under the Sales Agreement.
• A.G.P. will use commercially reasonable efforts to sell shares based on the Company's instructions, including price, time, or size limits.
• Sales will be conducted as an 'at-the-market' offering, as defined by Rule 415(a)(4) under the Securities Act of 1933.
• The Company will pay A.G.P. a commission of 3.0% of the aggregate gross proceeds from each sale of common stock.
• The Company has agreed to indemnify A.G.P. and reimburse certain specified expenses, including up to $40,000 for initial out-of-pocket expenses and up to $40,000 per fiscal year for maintenance expenses, plus $10,000 for each registration statement refresh.
• The shares will be offered pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-279036), filed May 1, 2024, and declared effective August 7, 2024, supplemented by a prospectus supplement dated December 19, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the potential for dilution exists, securing access to capital is a crucial and generally positive step for a biotech company, providing financial flexibility for future operations and development. The 'at-the-market' structure allows for opportunistic fundraising, which can be beneficial.

Positives

• Provides INmune Bio with flexible access to capital, allowing the company to raise funds as needed without a single large offering.
• The 'at-the-market' structure offers efficiency and potentially better pricing by selling into the open market over time.
• Secures up to $65,000,000 in potential funding, which can support ongoing operations, research and development, or other strategic initiatives for a biotech company.

Negatives

• The offering could lead to significant dilution for existing shareholders if a substantial portion of the $65 million is sold.
• The actual amount and timing of capital raised are uncertain, as the Company is not obligated to sell any shares, and sales depend on market conditions and A.G.P.'s efforts.
• A 3.0% commission on gross proceeds, plus expense reimbursements, will reduce the net proceeds received by the Company.

Risks

• Potential dilution of existing shareholders' equity due to the issuance of new common stock.
• Market conditions may not be favorable for selling shares, impacting the Company's ability to raise the desired capital or achieve optimal pricing.
• The Company's stock price could be negatively affected by the perception of future share sales and increased supply in the market.
• There is no guarantee that the full $65,000,000 will be raised, as the Company is not obligated to sell and the agent is only required to use commercially reasonable efforts.

Future Outlook

The filing indicates the Company's intent to maintain financial flexibility by establishing a mechanism for future capital raises. It does not provide specific forward-looking statements regarding operational performance, product development timelines, or revenue projections, but implies a need or desire for potential future funding to support its business activities.

Industry Context

At-the-market (ATM) offerings are a common financing tool, particularly for biotechnology and growth-stage companies, providing a flexible and cost-effective way to raise capital over time. This allows companies to tap into market demand opportunistically, funding ongoing research and development, clinical trials, or general corporate purposes without the immediate pricing pressure or larger discounts often associated with traditional underwritten offerings. The 3.0% commission is within the typical range for such agreements.

Comparison to Industry Standards

• The use of an at-the-market (ATM) offering is a standard practice for public companies, especially in the biotech sector, to access capital efficiently.
• The 3.0% commission rate for the sales agent is consistent with industry benchmarks for ATM offerings of this size and type.
• The maximum offering amount of $65 million provides a substantial funding runway, comparable to similar capital-raising efforts by other small to mid-cap biotech firms for R&D and operational expenses.

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings if new shares are issued, but also potential benefit from strengthened company finances for future growth.
• Company: Enhanced financial flexibility and access to capital for operations, research, and development.
• Creditors: Potentially improved financial stability and liquidity, reducing credit risk.

Next Steps

• The Company may issue Placement Notices to A.G.P. to initiate sales of common stock under the agreement.
• A.G.P. will use commercially reasonable efforts to sell shares based on the Company's instructions.
• The Company will file prospectus supplements and other required reports with the SEC detailing any sales made under the agreement.

Key Dates

Recommendation

The establishment of an at-the-market offering facility provides INmune Bio with crucial financial flexibility, which is generally positive for a biotech company requiring ongoing capital for R&D. However, the potential for future share dilution could exert downward pressure on the stock price. Without specific details on the immediate use of proceeds or a clear operational catalyst, a 'hold' recommendation is appropriate, advising investors to monitor the actual utilization of the facility and its impact on the company's balance sheet and share structure, balanced against any upcoming clinical or strategic milestones.

Keywords

INmune Bio, INMB, At-the-Market Offering, ATM, Equity Offering, Capital Raise, Common Stock, SEC Filing, Form 8-K, Shelf Registration, Dilution, Biotechnology, Pharmaceutical